Advances in therapies for systemic lupus erythematosus

CLINICAL THERAPY RESEARCH IN THE INFLAMMATORY DISEASES

Volumn , Issue , 2015, Pages 129-164

  Győri, Noémi ^a   Tani, Chiara ^b   Mosca, Marta ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84987600250     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. Block, S.R. (2006). A brief history of twins. Lupus, 15, 61-64.
2. Ramos, P.S., Brown, E.E., Kimberly, R.P., Langefeld, C.D. (2010). Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis. Semin Nephrol, 30, 164-176.
3. Fernando, M.M., Stevens, C.R., Sabeti, P.C., Walsh, E.C., McWhinnie, A.J., Shah, A., et al. (2007). Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet, 3, 192.
4. Graham, R.R., Ortmann, W., Rodine, P., Espe, K., Langefeld, C., Lange, E., et al. (2007). Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet, 15, 823-830.
5. Pickering, M.C., Botto, M., Taylor, P.R., Lachmann, P.J., Walport, M.J. (2000). Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol, 76, 227-324.
6. Mak, A., Tay, S.H. (2014). Environmental factors, toxicants and systemic Lupus Erythematosus. Int J Mol Sci. 15, 16043-16056.
7. Cleanthous, S., Tyagi, M., Isenberg, D.A., Newman, S.P. (2012). What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus, 21, 465-476.
8. Rovin, B.H., Tang, Y., Sun, J., Nagaraja, H.N., Hackshaw, K.V., Gray, L., et al. (2005). Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. Kidney Int, 68, 747-759.
9. Fernández, A., Quintana, G., Matteson, E.L., Restrepo, J.F., Rondón, F., Sánchez, A., Iglesias, A. (2004). Lupus arthropathy: historical evolution from deforming arthritis to rhupus. Clin Rheumatol, 23, 523-526.
10. Kuhn, A., Landmann, A. (2014). The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun, 48-49, 14-19.
11. Weening, J.J., D’Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., et al. (2004). The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol, 15, 241-250.
12. Doria, A., Iaccarino, L., Sarzi-Puttini, P., Atzeni, F., Turriel, M., Petri, M. (2005). Cardiac involvement in systemic lupus erythematosus. Lupus, 14, 683-686.
13. Carmier, D., Marchand-Adam, S., Diot, P., Diot, E. (2010). Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir, 27, e66-78.
14. Muscal, E., Brey, R.L. (2010). Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin, 28, 61-73.
15. Newman, K., Owlia, M.B., El-Hemaidi, I., Akhtari, M. (2013). Management of immune cytopenias in patients with systemic lupus erythematosus -old and new. Autoimmun Rev, 12, 784-791.
16. Barr, S.G., Zonana-Nacach, A., Magder, L. S, , Petri, M. (1999). Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum, 42, 2682-2688.
17. Gordon, C. (2002). Long-term complications of systemic lupus erythematosus. Rheumatology, 41, 1095-1100.
18. Griffiths, B., Mosca, M., Gordon, C. (2005). Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol, 19, 685-708.
19. Urowitz, M.B., Gladman, D.D., Tom, B.D., Ibañez, D., Farewell, V.T. (2008). Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol, 35, 2152-2158.
20. Ippolito, A., Petri, M. (2008). An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol, 26, S72-79.
21. van Vollenhoven, R.F., Mosca, M., Bertsias, G., Isenberg, D., Kuhn, A., Lerstrøm, K., et al. (2014). Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis, 73, 958-967.
22. Badsha, H., Kong, K.O., Lian, T.Y., Chan, S.P., Edwards, C.J., Chng, H.H. (2002). Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus, 8, 508-513.
23. Hoes, J.N., Jacobs, J.W.G., Boers, M., Boumpas, D., Buttgereit, F., Caeyers, N., et al. (2007). EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis, 66, 1560-1567.
24. van Vollenhoven, R.F. (1998). Corticosteroids in rheumatic disease. Understanding their effects is key to their use. Postgrad Med, 103(2), 137-142.
25. The Canadian hydroxychloroquine study group. (1998). A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus, 7, 80-85.
26. Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., et al. (2006). Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus, 15, 577-583.
27. Austin II, H.A., Klippel, J.H., Balow, J.E., le Richie, N.G., Steinberg, A.D., Plotz, P.H., et al. (1986). Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Eng J Med, 314, 614-619.
28. Boumpas, D.T., Austin, H.A. 3rd, Vaughn, E.M., Klippel, J.H., Steinberg, A.D., Yarboro, C.H., et al. (1992). Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, 340, 741-745.
29. Illei, G.G., Austin III, H.A., Crane, M., Collins, L., Gourley, M.F., Yarboro, C.H., et al. (2001). Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Int Med, 135, 248-257.
30. Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., de Ramon Garrido, E., Danieli, M.G., et al. (2002). Immunosuppressive therapy in lupus nephritis the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum, 46, 2121-2131.
31. Ioannidis, J.P., Katsifis, G.E., Tzioufas, A.G., Moutsopoulos, H.M. (2002). Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol, 29, 2129-2135.
32. Ognenovski, V., Marder, W., Somers, E.C., Johnston, C.M., Ferrehi, J.G., Selvaggi, S.M., et al. (2004). Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol, 31, 1763-1767.
33. Touma, Z., Gladman, D.D., Urowitz, M.B., Beyene, J., Uleryk, E.M., Shah, P.S. (2011). Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis. J Rheumatol, 38, 69-78.
34. Maneiro, J.R., Lopez-Canoa, N., Salgado, E., Gomez-Reino, J.J. (2014). Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology, 53, 834-838.
35. Callen, J.P., Spencer, L.V., Burruss, J.B., Holtman, J. (2001). Azathioprine: an effective, corticosterois sparing therapy for patients with recalcitrant cutab2080_ neous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol, 127, 515-522.
36. Sakthiswary, R., Suresh, E. (2014). Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus, 23, 225-235.
37. Navarra, S.V., Guzman, R.M., Gallacher, A.E., Hall, S., Levy, R.A., Jimenez, R.E., et al. (2011). Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, 377, 721-731.
38. Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D.J., Tegzová, D. (2011). A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum, 63, 3918-3930.
39. van Vollenhoven, R.F., Petri, M.A., Cervera, R., Roth, D.A., Ji, B.N., Kleoudis, C.S., et al. (2012). Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis, 71, 1343-1349.
40. Manzi, S., Sanchez-Guerrero, J., Merrill, J.T., Furie, R., Gladman, D., et al. (2012). Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis, 71, 1833-1838.
41. Ginzler, E.M., Wallace, D.J., Merrill, J.T., Furie, R.A., Stohl, W., Chatham, W.W., et al. (2014). Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol, 41, 300-309.
42. Strand, V., Levy, R.A., Cervera, R., Petri, M.A., Birch, H., Freimuth, W.W., et al. (2014). Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibodypositive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis, 73, 838-844.
43. Parodis, I., Svenungsson, E., Axelsson, M. and Gunnarsson, I. (2014). Decreased disease activity and corticosteroid usage and no renal flares during belimumab treatment in patients with systemic lupus erythematosus. Arthritis and Rheum, 66, 11 (Supplement).
44. Dooley, M.A., Houssiau, F., Aranow, C., D’Cruz, D.P., Askanase, A., Roth, D.A., et al. (2013). Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus, 22, 63-72.
45. Ekö, S.L., van Vollenhoven, R.F. (2014). Rituximab and lupus-a promising pair? Curr Rheumatol Rep, 16, 444.
46. Gunnarsson, I., Sundelin, B., Jónsdóttir, T., Jacobson, S.H., Henriksson, E.W., van Vollenhoven, R.F. (2007). Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum, 56, 1263-1272.
47. Condon, M.B., Ashby, D., Pepper, R.J., Cook, H.T., Levy, J.B., Griffith, M., et al. (2013). Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis, 72, 1280-1286.
48. Wallace, D.J., Gordon, C., Strand, V., Hobbs, K., Petri, M., Kalunian, K., et al. (2013). Efficacy and safety of epratuzumab in patients with moderate/ severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology, 52, 1313-1322.
49. Strand, V., Petri, M., Kalunian, K., Gordon, C., Wallace, D.J., Hobbs, K., et al. (2014). Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology, 53, 502-511.
50. Wallace, D.J., Kalunian, K., Petri, M.A., Strand, V., Houssiau, F.A., Pike, M., et al. (2014). Efficacy and safety of epratuzumab in patients with moderate/ severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis, 73, 183-190.
51. Furie, R.A., Leon, G., Thomas, M., Petri, M.A., Chu, A.D., Hislop, C., et al. (2014). A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis.
52. https://investor.lilly.com/releasedetail.cfm?ReleaseID=874281
53. Ginzler, E.M., Wax, S., Rajeswaran, A., Copt, S., Hillson, J., Ramos, E., et al. (2012). Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther, 14(1): R33.
54. Wofsy, D., Isenberg, D., Licu, D. (2013). Efficacy and safety of atacicept for prevention of flares in subjects with moderate to severe systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheum, 65(Suppl 10), 1591.
55. Kieseier, B.C. (2014). Defining a role for laquinimod in multiple sclerosis. Ther Adv Neurol Disord, 7(4), 195-205.
56. Jayne, D., Appel, G., Chan, T.M., Barkay, H., Weiss, R., Wofsy, D. (2013). A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis, 72, 164.
57. Illei, G.G., Shirota, Y., Yarboro, C.H., Daruwalla, J., Tackey, E., Takada, K., et al. (2010). Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an openlabel phase I dosage-escalation study. Arthritis Rheum, 62, 542.
58. Shirota, Y., Yarboro, C., Fischer, R., Pham, T.H., Lipsky, P., Illei, G.G., et al. (2013). Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis, 72, 118-128.
59. Szepietowski, J.C., Nilganuwong, S., Wozniacka, A., Kuhn, A., Nyberg, F., van Vollenhoven, R.F., et al. (2013). Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum, 65, 2661-2671.
60. Merrill, J.T., Wallace, D.J., Petri, M., Kirou, K.A., Yao, Y., White, W.I., et al. (2011). Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis, 70, 1905-1913.
61. Petri, M., Wallace, D.J., Spindler, A., Chindalore, V., Kalunian, K., Mysler, E., et al. (2013). Sifalimumab, a human anti-interferon-a monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, doseescalation study. Arthritis Rheum, 65, 1011-1021.
62. McBride, J.M., Jiang, J., Abbas, A.R., Morimoto, A., Li, J., Maciuca, R., et al. (2012). Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double- blind, dose-escalation study. Arthritis Rheum, 64(11), 3666-3676.
63. Kalunian, K., Merrill, J.T., Maciuca, R. (2012). Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebocontrolled phase 2 study [abstract]. Arthritis Rheum, 64(Suppl 10), 2622.
64. Mosca, M., Tani, C., Aringer, M., Bombardieri, S., Boumpas, D., Brey, R., et al. (2010). European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis, 69, 1269-1274.
65. Bruce, I.N. (2005). Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol, 19, 823-838.
66. Toloza, S.M., Cole, D.E., Gladman, D.D., Ibañez, D., Urowitz, M.B. (2010). Vitamin D insufficiency in a large female SLE cohort. Lupus. 19, 13-19.